Spruce Biosciences, Inc. (SPRB)
Automate Your Wheel Strategy on SPRB
With Tiblio's Option Bot, you can configure your own wheel strategy including SPRB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SPRB
- Rev/Share 2.1425
- Book/Share 21.7386
- PB 6.4645
- Debt/Equity 0.1383
- CurrentRatio 2.5996
- ROIC -3.3771
- MktCap 79125276.0
- FreeCF/Share -84.8681
- PFCF -1.5378
- PE -1.7626
- Debt/Assets 0.0835
- DivYield 0
- ROE -1.7745
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 5
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | SPRB | JMP Securities | Mkt Outperform | Market Perform | -- | -- | Dec. 11, 2024 |
| Downgrade | SPRB | Oppenheimer | Outperform | Perform | -- | -- | Dec. 11, 2024 |
News
What Makes Spruce Biosciences, Inc. (SPRB) a Strong Momentum Stock: Buy Now?
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Spruce Biosciences, Inc. (SPRB) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Spruce: BTD For TA-ERT For MPS IIIB Could Ignite BLA Submission With Added Bonuses (Rating Upgrade)
Published: October 07, 2025 by: Seeking Alpha
Sentiment: Positive
Spruce Biosciences received FDA Breakthrough Therapy Designation for TA-ERT in treating San Filippo Syndrome Type B [MPS IIIB]. BTD enables potential rolling BLA submission, Priority Review, and Accelerated Approval pathway, supported by strong 5-year biomarker and clinical data for TA-ERT. Company plans to file a BLA for TA-ERT for MPS IIIB patients in Q1 2026, aiming to deliver the first disease-modifying therapy for them.
Read More
HMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder
Published: July 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
Study Initiation Marks Key Milestone in Advancing Precision Psychiatry Treatment for Major Depressive Disorder Topline Results Anticipated in the First Half of 2026 MUNICH, Germany and SOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC”), a global precision psychiatry biopharmaceutical company, in collaboration with Spruce Biosciences, Inc. (OTCQB: SPRB) (“Spruce”), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced that the first patient has been dosed in the Phase 2 clinical trial called “Tildacerfont as Antidepressant Medication and Relief in Depression” (TAMARIND).
Read More
About Spruce Biosciences, Inc. (SPRB)
- IPO Date 2020-10-09
- Website https://www.sprucebiosciences.com
- Industry Biotechnology
- CEO Javier Szwarcberg
- Employees 20